IO Biotech, Inc. IOBTQ

IOBTQ Company Overview

IO Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, immune-modulating cancer therapies. The company operates within the biotechnology and oncology immunotherapy industries, with a core emphasis on therapeutic cancer vaccines designed to activate T cells against immune-suppressive targets in the tumor microenvironment. Its primary value proposition is the development of off-the-shelf peptide-based immunotherapies intended to be used in combination with existing immune checkpoint inhibitors.

The company’s lead product candidate is IO102/IO103, a dual-antigen therapeutic cancer vaccine targeting indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). IO Biotech was founded in 2014 in Copenhagen, Denmark, as IO Biotech ApS and later established a U.S. holding company structure. The company completed its initial public offering in 2021 and is listed on the Nasdaq under the ticker IOBT, transitioning from a private research-focused organization to a publicly traded clinical-stage developer.